Abstract
Although novel retroviral vectors for use in gene-therapy products are reducing the potential for formation of replication-competent retrovirus (RCR), it remains crucial to screen products for RCR for both research and clinical purposes. For clinical-grade gammaretrovirus-based vectors, RCR screening is achieved by an extended S+ L- or marker-rescue assay, whereas standard methods for replication-competent lentivirus detection are still in development. In this report, we describe a rapid and sensitive method for replication-competent gammaretrovirus detection. We used this assay to detect three members of the gammaretrovirus family and compared the sensitivity of our assay with well-established methods for retrovirus detection, including the extended S+ L- assay. Results presented here demonstrate that this assay should be useful for gene-therapy product testing.
Original language | English |
---|---|
Pages (from-to) | 169-176 |
Number of pages | 8 |
Journal | Gene Therapy |
Volume | 20 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2013 |
Fingerprint
Keywords
- Gene-therapy vectors
- Infectivity assay
- Replication-competent gammaretrovirus
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
Cite this
A reporter system for replication-competent gammaretroviruses : the inGluc-MLV-DERSE assay. / Aloia, A. L.; Duffy, L.; Pak, V.; Lee, K. E.; Sanchez-Martinez, S.; Derse, D.; Heidecker, G.; Cornetta, Kenneth; Rein, A.
In: Gene Therapy, Vol. 20, No. 2, 02.2013, p. 169-176.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A reporter system for replication-competent gammaretroviruses
T2 - the inGluc-MLV-DERSE assay
AU - Aloia, A. L.
AU - Duffy, L.
AU - Pak, V.
AU - Lee, K. E.
AU - Sanchez-Martinez, S.
AU - Derse, D.
AU - Heidecker, G.
AU - Cornetta, Kenneth
AU - Rein, A.
PY - 2013/2
Y1 - 2013/2
N2 - Although novel retroviral vectors for use in gene-therapy products are reducing the potential for formation of replication-competent retrovirus (RCR), it remains crucial to screen products for RCR for both research and clinical purposes. For clinical-grade gammaretrovirus-based vectors, RCR screening is achieved by an extended S+ L- or marker-rescue assay, whereas standard methods for replication-competent lentivirus detection are still in development. In this report, we describe a rapid and sensitive method for replication-competent gammaretrovirus detection. We used this assay to detect three members of the gammaretrovirus family and compared the sensitivity of our assay with well-established methods for retrovirus detection, including the extended S+ L- assay. Results presented here demonstrate that this assay should be useful for gene-therapy product testing.
AB - Although novel retroviral vectors for use in gene-therapy products are reducing the potential for formation of replication-competent retrovirus (RCR), it remains crucial to screen products for RCR for both research and clinical purposes. For clinical-grade gammaretrovirus-based vectors, RCR screening is achieved by an extended S+ L- or marker-rescue assay, whereas standard methods for replication-competent lentivirus detection are still in development. In this report, we describe a rapid and sensitive method for replication-competent gammaretrovirus detection. We used this assay to detect three members of the gammaretrovirus family and compared the sensitivity of our assay with well-established methods for retrovirus detection, including the extended S+ L- assay. Results presented here demonstrate that this assay should be useful for gene-therapy product testing.
KW - Gene-therapy vectors
KW - Infectivity assay
KW - Replication-competent gammaretrovirus
UR - http://www.scopus.com/inward/record.url?scp=84873568204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873568204&partnerID=8YFLogxK
U2 - 10.1038/gt.2012.18
DO - 10.1038/gt.2012.18
M3 - Article
C2 - 22402321
AN - SCOPUS:84873568204
VL - 20
SP - 169
EP - 176
JO - Gene Therapy
JF - Gene Therapy
SN - 0969-7128
IS - 2
ER -